Financials Recursion Pharmaceuticals, Inc.

Equities

RXRX

US75629V1044

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 24/05/2024 BST 5-day change 1st Jan Change
9.16 USD +1.44% Intraday chart for Recursion Pharmaceuticals, Inc. -2.76% -7.10%

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 2,895 1,461 2,136 2,177 - -
Enterprise Value (EV) 1 2,379 918.1 1,745 1,819 1,841 1,822
P/E ratio -11.5 x -5.67 x -6.24 x -5.57 x -5.03 x -8.57 x
Yield - - - - - -
Capitalization / Revenue 284 x 36.7 x 47.9 x 37 x 34.5 x 14.4 x
EV / Revenue 234 x 23 x 39.2 x 30.9 x 29.2 x 12 x
EV / EBITDA -13.6 x -3.92 x -5.36 x -4.44 x -3.63 x -3.5 x
EV / FCF -12 x -7.61 x -5.82 x -5.85 x -5.04 x -8.24 x
FCF Yield -8.34% -13.1% -17.2% -17.1% -19.8% -12.1%
Price to Book 5.37 x 2.79 x 4.97 x 5.5 x 8.34 x 10.2 x
Nbr of stocks (in thousands) 168,993 189,556 216,623 237,664 - -
Reference price 2 17.13 7.710 9.860 9.160 9.160 9.160
Announcement Date 23/03/22 27/02/23 27/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3.962 10.18 39.84 44.58 58.86 63.02 151.4
EBITDA 1 - -174.4 -234 -325.7 -409.7 -506.7 -520.5
EBIT 1 - -182.8 -245.7 -350.1 -426 -508.4 -478.8
Operating Margin - -1,795.79% -616.74% -785.33% -723.73% -806.68% -316.2%
Earnings before Tax (EBT) - -186.5 -239.5 -332.1 - - -
Net income 1 -87.01 -186.5 -239.5 -328.1 -401.5 -472.5 -347.2
Net margin -2,196.01% -1,832.18% -601.05% -735.99% -682.13% -749.68% -229.24%
EPS 2 -5.990 -1.490 -1.360 -1.580 -1.644 -1.820 -1.069
Free Cash Flow 1 - -198.4 -120.6 -299.7 -311 -365 -221
FCF margin - -1,949.42% -302.65% -672.43% -528.38% -579.17% -145.94%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - - - - -
Announcement Date 03/03/21 23/03/22 27/02/23 27/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 2.533 5.333 7.674 13.16 13.68 12.13 11.02 10.53 10.89 13.79 13.75 13.93 15.37 15.1 15.35
EBITDA 1 - - - -59.58 - -66.14 -76.17 - -91.38 - -89 -88.3 -182.1 -198.7 -202.7
EBIT 1 -64.96 -55.98 -66.19 -62.57 -60.98 -69.86 -81.72 -99.55 -98.93 -96.34 -102.4 -106.5 -130.6 -153.6 -155.5
Operating Margin -2,564.55% -1,049.71% -862.54% -475.48% -445.91% -575.78% -741.72% -945.12% -908.36% -698.42% -744.57% -764.26% -849.67% -1,016.89% -1,013.03%
Earnings before Tax (EBT) 1 -64.93 - -65.56 -60.44 -57.49 -65.33 -76.73 -93.02 -94.62 -92.15 -97 -98 -104 - -
Net income 1 -64.93 -55.98 -65.56 -60.44 -57.49 -65.33 -76.73 -93.02 -93 -91.37 -96.9 -97.25 -123.6 -153.6 -155.6
Net margin -2,563.48% -1,049.67% -854.31% -459.31% -420.39% -538.38% -696.43% -883.1% -853.88% -662.41% -704.73% -697.97% -804.5% -1,017.22% -1,013.68%
EPS 2 -0.3800 -0.3300 -0.3800 -0.3500 -0.3000 -0.3400 -0.3800 -0.4300 -0.4200 -0.3900 -0.3994 -0.3925 -0.4755 -0.6650 -0.6650
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 23/03/22 10/05/22 09/08/22 08/11/22 27/02/23 08/05/23 08/08/23 09/11/23 27/02/24 09/05/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - 516 543 390 358 336 355
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - -198 -121 -300 -311 -365 -221
ROE (net income / shareholders' equity) - -111% -46.6% -69.1% -91.7% -126% -125%
ROA (Net income/ Total Assets) - -41% -36.5% -48.4% -63.6% -86.7% -63.7%
Assets 1 - 454.5 655.8 677.5 631.8 544.8 545.1
Book Value Per Share 2 - 3.190 2.770 1.980 1.670 1.100 0.9000
Cash Flow per Share 2 - -1.270 -0.4800 -1.380 -1.050 -0.6400 -
Capex 1 - 39.8 37.1 12 13 14 16
Capex / Sales - 391.02% 93.01% 26.82% 22.09% 22.21% 10.57%
Announcement Date 03/03/21 23/03/22 27/02/23 27/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
9.16 USD
Average target price
13 USD
Spread / Average Target
+41.92%
Consensus
  1. Stock Market
  2. Equities
  3. RXRX Stock
  4. Financials Recursion Pharmaceuticals, Inc.